can you take semaglutide with graves disease and Thyroid Disease: Safety Guide Semaglutide and Synthroid Together: Safety

29 Comparative analysis Comparisons of multiple peptide GLP-1 RAs with respect to weight loss and adverse effects have found that these medications are more effective than placebo in reducing body weight (BW) (3.11 kg, CI: 3.64 to 2.57 kg)

Carbonated and fizzy drinks the extra gas can add to bloating and discomfort

K.GoudaG.VaddeR

Weighted cumulative incidence for MACE, from Lambourg et al , Am J Kidney Dis, 2025 Cause-specific mortality Stopping metformin was associated with an increased risk of respiratory death (HR 1.51, 95% CI 1.06-2.12) but not cancer mortality (HR 1.07, 95% CI, 0.80-1.44)

The glucose-dependent T2D therapies such as glucagon-like peptide-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 inhibitors, promote glucose control by minimizing both hyperglycaemia and hypoglycaemia